SS Innovations International Inc. (SSII) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, SSII carries an RQD Score of 30 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 5 / 20 (ROIC -18.5%; FCF yield -4.65%), indicating the business is not currently generating returns on invested capital or positive free cash flow. Whale 13F flow scores 3 / 20 and insider conviction scores 3 / 20, reflecting weak institutional and insider-signal support as described in the rating's pillar labels. Macro regime fit scores 5 / 20 (Beta 1.0; sector sensitivity). Forensic balance sheet is the strongest pillar at 14 / 20 (Altman Z 7.47; Piotroski F 4/9; Debt/Equity 0.5), suggesting the balance sheet is less fragile than the cash-flow and ownership signals. For a prospective investor, the practical implication is that any upside case must rest on a future turn in cash generation, since the rating does not identify an existing cash engine; the balance-sheet score offers some cushion but does not offset negative returns and weak flow signals. This is an analytical framing, not personalized advice.

Per the profile, SS Innovations International Inc. is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the news wire, the company is associated with telerobotic surgery, including the SSi Mantra Surgical Robotic System for which an FDA response was submitted. Per the market data, gross margin is 46%. Revenue and customer-level details beyond these items are not available in source data.

Per the SEC financials, revenue rose across the three reported periods while operating and net losses persisted in each. Per the market data, operating margin is -19.3% and net margin is -28.5%. ROIC is -18.5% and the Altman Z-Score is 7.47, with a Piotroski F-Score of 4/9 per the forensic balance-sheet pillar of the RQD rating. Debt/Equity is listed as 0.5 per the rating, while the debt line item in the financials is N/A.

Per the news wire, the most recent items include a CATALYST headline on telerobotic surgery position-building, a MARKET WIRE item on FDA response submission for the SSi Mantra system, a RISK WATCH item noting a 32% three-month decline, a CATALYST item on a remote heart-surgery procedure, a CATALYST item on conference showcases of telesurgery capabilities, and a MARKET WIRE item on the stock trading near the midpoint of its range. The RISK WATCH item is the sole flagged risk; the remaining items are catalyst or market-wire classified. Per the Butterfly Supply-Chain Graph, the sector is Health Care, industry is Medical/Dental Instruments, supply chain is NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, no upstream or downstream links are recorded (supply_chain: NONE; butterfly_links: empty). Sector correlations, second-order bottlenecks, and dependency mapping are therefore not available in source data. The only sector context provided is the Health Care / Medical-Dental Instruments classification and the Beta of 1.0 per the rating's macro pillar.

• What is the source of the negative operating and free cash flow trend, and what path to positive cash generation does management outline?
• What is the debt balance behind the reported Debt/Equity of 0.5, given the debt line is N/A in the financials?
• What is the status and timeline of the FDA review for the SSi Mantra system, and what regulatory risk remains?
• What drove the 32% three-month decline, and is it tied to fundamentals or to ownership/flow factors?
• Why do the EPS and forward valuation metrics remain unreported, and how does the company's profitability trajectory compare with the revenue growth shown?